Factor VIII - China Biologic Products

Drug Profile

Factor VIII - China Biologic Products

Alternative Names: Human coagulation factor VIII - China Biologics; Human coagulation factor VIII - Shandong Taibang

Latest Information Update: 25 Aug 2013

Price : $50

At a glance

  • Originator China Biologic Products; Shandong Taibang Biological Products
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A
  • Discontinued Haemorrhage

Most Recent Events

  • 06 Aug 2013 Launched for Haemophilia A in China (IV) before August 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top